Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 6, 2009, Pages 1323-1331

  Nilsson, Henrik ^a   Nordell, Anders ^b   Vargas, Roberto ^b   Douglas, Lena ^b   Jonas, Eduard ^a   Blomqvist, Lennart ^a,b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Deconvolutional analysis; DHCE MRI; Gd EOB DTPA; Hepatic extraction fraction; Liver function test; Magnetic resonance imaging

Indexed keywords

ETHOXYBENZYLDIETHYLENETRIAMINE; GADOLINIUM; PENTETIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPUTER SIMULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOURIER ANALYSIS; HUMAN; HUMAN EXPERIMENT; LIVER BLOOD FLOW; LIVER CELL; LIVER FUNCTION; MALE; MATHEMATICAL ANALYSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO; TRUNCATED SINGULAR VALUE DECOMPOSITION;

ADULT; CONTRAST MEDIA; FEASIBILITY STUDIES; FOURIER ANALYSIS; GADOLINIUM DTPA; HEPATOCYTES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 66749184079     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21801     Document Type: Article

References (38)

1. Krishnamurthy GT, Turner FE. Pharmacokinetics and clinical application of technetium 99m-labeled hepatobiliary agents. Semin Nucl Med 1990;20:130-149.
2. Jonas E, Hultcrantz R, Slezak P, Blomqvist L, Schnell PO, Jacobsson H. Dynamic 99Tcm-HIDA SPET: non-invasive measuring of intrahepatic bile flow. Description of the method and a study in primary sclerosing cholangitis. Nucl Med Commun 2001;22:127-134.
3. Jonas E, Naslund E, Freedman J, et al. Measurement of parenchymal function and bile duct flow in primary sclerosing cholangitis using dynamic 99mTc-HIDA SPECT. J Gastroenterol Hepatol 2006; 21:674-681.
4. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266-275. (Pubitemid 37549812)
5. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007;6:43-52.
6. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761.
7. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
8. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997;7:683-688. (Pubitemid 28365618)
9. Murakami T, Kim T, Gotoh M, et al. Experimental hepatic dysfunction: evaluation by MR imaging with Gd-EOB-DTPA. Acad Radiol 1998;5(Suppl 1):S80-S82.
10. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004;5: 231-239.
11. Schmitz SA, Muhler A, Wagner S, Wolf KJ. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol 1996;31:154-160.
12. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 1999;44:1330-1337. (Pubitemid 29404293)
13. Planchamp C, Gex-Fabry M, Becker CD, Pastor CM. Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers. Invest Radiol 2007;42:513-521. (Pubitemid 46955246)
14. Planchamp C, Gex-Fabry M, Dornier C, et al. Gd-BOPTA transport into rat hepatocytes: pharmacokinetic analysis of dynamic magnetic resonance images using a hollow-fiber bioreactor. Invest Radiol 2004;39:506-515. (Pubitemid 38982154)
15. Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, Gex- Fabry M. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Invest Radiol 2005;40:705-714. (Pubitemid 41546837)
16. Juni JE, Thrall JH, Froelich JW, Wiggins RC, Campbell DA Jr, Tuscan M. The appended curve technique for deconvolutional analysis- method and validation. Eur J Nucl Med 1988;14:403-407. (Pubitemid 18221188)
17. Brown PH, Juni JE, Lieberman DA, Krishnamurthy GT. Hepatocyte versus biliary disease: a distinction by deconvolutional analysis of technetium-99m IDA time-activity curves. J Nucl Med 1988;29: 623-630. (Pubitemid 18143612)
18. Davenport R. The derivation of the gamma-variate relationship for tracer dilution curves. J Nucl Med 1983;24:945-948. (Pubitemid 14236778)
19. Strasberg SM. Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. J Am Coll Surg 1997;184:413-434. (Pubitemid 27172831)
20. Lieberman DA, Brown PH, Krishnamurthy GT. Improved scintigraphic assessment of severe cholestasis with the hepatic extraction fraction. Dig Dis Sci 1990;35:1385-1390. (Pubitemid 20377969)
21. Hawkins RA, Hall T, Gambhir SS, et al. Radionuclide evaluation of liver transplants. Semin Nucl Med 1988;18:199-212.
22. Juni JE, Reichle R. Measurement of hepatocellular function with deconvolutional analysis: application in the differential diagnosis of acute jaundice. Radiology 1990;177:171-175. (Pubitemid 20317343)
23. Tagge EP, Campbell DA Jr, Reichle R, et al. Quantitative scintigraphy with deconvolutional analysis for the dynamic measurement of hepatic function. J Surg Res 1987;42:605-612. (Pubitemid 17103649)
24. Daniel GB, DeNovo R, Schultze AE, Schmidt D, Smith GT. Validation of deconvolutional analysis for the measurement of hepatic function in dogs with toxic-induced liver disease. Vet Radiol Ultrasound 1998;39:375-383. (Pubitemid 128462675)
25. Wirestam R, Andersson L, Ostergaard L, et al. Assessment of regional cerebral blood flow by dynamic susceptibility contrast MRI using different deconvolution techniques. Magn Reson Med 2000; 43:691-700. (Pubitemid 30244268)
26. Ostergaard L. Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging 2005;22:710-717. (Pubitemid 41741235)
27. Murase K, Yamazaki Y, Miyazaki S. Deconvolution analysis of dynamic contrast-enhanced data based on singular value decomposition optimized by generalized cross validation. Magn Reson Med Sci 2004;3:165-175.
28. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. I. Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
29. Jacobsson H, Hellstrom PM, Kogner P, Larsson SA. Different concentrations of I-123 MIBG and In-111 pentetreotide in the two main liver lobes in children: persisting regional functional differences after birth? Clin Nucl Med 2007;32:24-28.
30. Jacobsson H, Jonas E, Hellstrom PM, Larsson SA. Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients. J Gastroenterol 2005;40:733-738. (Pubitemid 41349085)
31. Rowland M, Tozer T. Clinical pharmacokinetics, concepts and applications. Philadelphia: Lea & Febiger; 1995. 601 p.
32. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology 2005;234:661-673. (Pubitemid 40250807)
33. Rusinek H, Lee VS, Johnson G. Optimal dose of Gd-DTPA in dynamic MR studies. Magn Reson Med 2001;46:312-316. (Pubitemid 32703277)
34. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40:715-724. (Pubitemid 41546838)
35. Burke MD. Liver function: test selection and interpretation of results. Clin Lab Med 2002;22:377-390. (Pubitemid 34755909)
36. Burra P, Masier A. Dynamic tests to study liver function. Eur Rev Med Pharmacol Sci 2004;8:19-21. (Pubitemid 38659918)
37. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores-where are we and where should we go? J Hepatol 2004;41:344-350.
38. Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007;204:854-862; discussion 862-1854 (Pubitemid 46661186)